Track market-moving stories before they get noisy

, /PRNewswire/ --

FMC Corporation (NYSE: FMC) announced today that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on October 15, 2026, to shareholders of record as of the close of business on September 30, 2026.   

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995: FMC and its representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, in FMC's other filings with the SEC, and in presentations, reports or letters to FMC stockholders.

In some cases, FMC has identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaims any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

SOURCE FMC Corporation

Key Takeaways FMC submitted its first global regulatory dossier for rimisoxafen to the U.S. EPA.Rimisoxafen is classified as a dual mode of action herbicide in Groups 12 and 32.FMC plans more approvals after advancing its third novel herbicide to regulatory submission. FMC Corporation (FMC - Free Report) has announced the submission of its first global regulatory dossier for rimisoxafen, its novel herbicide active ingredient, to the U.S. Environmental Protection Agency. It marks the first regulatory submission globally that seeks approval for use on corn, soybean, sunflower, and select pulse crops, marking the beginning of the product's regulatory process.

Developed at FMC's Stine Research Center after a decade of research and more than 1,000 field and greenhouse studies, rimisoxafen is the first herbicide active ingredient to be classified by the Global Herbicide Resistance Action Committee as a dual mode of action herbicide. It has been assigned to Groups 12 and 32 and uses two separate biochemical pathways in weeds to slow down resistance development.

As Palmer amaranth and waterhemp continue to threaten crops, rimisoxafen is expected to be highly effective against these broadleaf weeds, addressing the challenges faced by growers spending more than $6 billion annually on weed control with more than 70 million hectares of corn and soybean grown annually.

Rimisoxafen is the third novel herbicide active ingredient the company has advanced to regulatory submission in recent years, following Isoflex active and Dodhylex active. The company plans to pursue approvals in additional key geographies and crop segments as part of its development strategy. The herbicide is awaiting approval to be eligible for commercial sale or use of the product.

FMC’s shares have slumped 74.4% over the past year compared with the industry’s 9.3% rise.

Image Source: Zacks Investment Research

FMC’s Zacks Rank & Key PicksFMC currently carries a Zacks Rank #5 (Strong Sell). 

Some better-ranked stocks in the Basic Materials space are Albemarle Corporation (ALB - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Avino Silver & Gold Mines Ltd. (ASM - Free Report) .

While ALB sports a Zacks Rank #1 (Strong Buy) at present, CRS and ASM carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for ALB’s 2026 earnings is pinned at $12.98 per share, indicating a 1,743.04% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed one, with an average surprise of 74.5%. ALB’s shares have jumped 74.2% over the past year.

The Zacks Consensus Estimate for CRS’ 2026 earnings is pegged at $10.56 per share, indicating a rise of 41.18% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.95%.

The Zacks Consensus Estimate for ASM’s current fiscal-year earnings is pinned at 34 cents per share, indicating a 17.24% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 125%. ASM’sshares have gained 46.9% over the past year.

Key Takeaways FMC signed a definitive agreement for a $400 million minority equity investment with Tessenderlo Group. FMC will use most proceeds to reduce debt, supporting its $1 billion repayment target and R&D investment. Tessenderlo Group said the investment aligns with its strategy and FMC's crop technology growth potential. FMC Corporation (FMC - Free Report) has entered into a definitive agreement with Belgium-based Tessenderlo Group for a minority equity investment of approximately $400 million. Tessenderlo Group will purchase FMC shares at $13.30 per share, and upon completion of the transaction, it will own about 20% of FMC's outstanding common stock. The deal is subject to customary closing conditions, including regulatory approvals. 

The investment marks the conclusion of FMC's strategic options review, which the company's board initiated in February 2026 to strengthen its financial position and maximize shareholder value. 

FMC plans to use the proceeds primarily to reduce debt, allowing it to achieve its previously announced target of approximately $1 billion in debt repayment. Management believes the stronger capital structure will support continued investment in research and development and to accelerate the commercialization of its proprietary crop protection technologies. 

The transaction follows several financial initiatives undertaken in recent months to strengthen liquidity and unlock capital. These include amending its revolving credit facility to obtain covenant relief, raising $1.2 billion through a secured high-yield bond offering, agreeing to sell its India commercial business for $252 million, signing a supply and license agreement with Corteva that includes an initial $200 million prepayment, and entering into a $114 million sale-and-leaseback agreement for its Newark, DE, property. 

Per Tessenderlo Group, the investment supports its strategy of acquiring minority stakes in high-quality businesses while expanding its agricultural platform. It also cited FMC's long-term growth potential, driven by its next-generation proprietary crop protection technologies. 

Per FMC, the agreement reflects a comprehensive review process and positions the company to execute its operational and strategic plan with improved leverage and liquidity. The company expects the strengthened financial position to enhance its ability to serve customers while delivering long-term value to shareholders.  

Shares of FMC have plunged 74.1% in the past year against the industry’s 3.8% rise. 

Image Source: Zacks Investment Research

FMC’s Zacks Rank & Key PicksFMC currently carries a Zacks Rank #4 (Sell). 

Some better-ranked stocks in the Consumer Staples space are ARKO Corp. (ARKO - Free Report) , Darling Ingredients Inc. (DAR - Free Report) and Fomento Económico Mexicano, S.A.B. de C.V. (FMX - Free Report) . ARKO, DAR and FMX carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. 

The Zacks Consensus Estimate for ARKO’s current-year earnings stands at 29 cents per share, implying a 93.3% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with the average surprise being 43.2%. 

The Zacks Consensus Estimate for DAR’s current-year earnings is pegged at $4.59 per share, implying a 576% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, with the average surprise being 14.8%. 

The Zacks Consensus Estimate for FMX’s current-year earnings is pegged at $5.77 per share, indicating a 115.4% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in one of the trailing four quarters and missed thrice. 

Tessenderlo Group's investment reflects its strategy of making cornerstone minority investments in high-quality companies Investment enables FMC to achieve approximately $1 billion debt paydown target FMC concludes strategic options review FMC maintains focus on delivering on its operational and strategic plan , /PRNewswire/ -- FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, and Tessenderlo Group (XBRU: TESB), a Belgian-based industrial group, today announced that they have entered into a definitive agreement under which Tessenderlo Group will make a strategic minority equity investment in FMC Corporation of approximately $400 million USD at a price of $13.30 per share. Upon completion of the transaction, Tessenderlo Group will own approximately 20.0% of the outstanding shares of FMC common stock.

"Our investment in FMC perfectly aligns with Tessenderlo Group's strategy to expand our agro platform through strategic cornerstone investments whereby we take a minority position in high-quality companies. FMC offers an attractive opportunity to invest in a business with meaningful long-term potential driven by a new generation of proprietary molecules that are renewing its portfolio and strengthening its competitive position," said Luc Tack, chief executive officer, Tessenderlo Group.

"This agreement follows a comprehensive and deliberate process, and our Board is confident that entering into this agreement is the best path forward for our company and its shareholders," said Pierre Brondeau, chairman, chief executive officer and president.

This transaction represents the conclusion of the FMC Board of Directors' exploration of strategic options, which was announced in February 2026. FMC intends to use the funds to pay down debt, allowing the Company to reach its approximately $1 billion debt paydown target. With this investment, FMC is well positioned to execute on its operational and strategic plan as an independent company, which includes advancing its R&D pipeline and accelerating the commercialization of its innovations.

In addition to the investment by Tessenderlo Group, over the past several months, FMC has taken a number of steps toward its goals of unlocking capital, sharpening its strategic focus and improving financial flexibility, including:

Amended its Revolving Credit Facility to achieve significant covenant relief;   Raised $1.2 billion in a secured high-yield bond offering; Signed an agreement to sell the Company's India commercial business for $252 million; Entered into a strategic supply and license agreement with Corteva, Inc., which includes an initial prepayment of $200 million; and Signed a framework agreement for a $114 million sale & leaseback of its Newark, Delaware property. Brondeau concluded, "We believe the strategic and operational actions taken by FMC over the last several months, combined with our significantly improved leverage and liquidity position, will deliver value to our shareholders, putting FMC on a path to growth as we strongly serve our customers and markets."

The closing of the transaction is subject to customary conditions, including the receipt of regulatory approvals.

BofA Securities and Goldman Sachs & Co. LLC are serving as financial advisors and Davis Polk & Wardwell LLP is serving as legal counsel to FMC Corporation.

Stibbe BV/SRL and Sullivan & Cromwell LLP are serving as legal advisors to Tessenderlo Group NV.

About FMC
FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

About Tessenderlo Group
Tessenderlo Group is an industrial group that focuses on agriculture, valorising bio-residuals, machinery, mechanical engineering, electronics, energy, and providing industrial solutions with a focus on water. With its headquarters in Belgium, the group is active in over 100 countries and it has a global team of approximately 7,000 employees. Its belief that "Every Molecule Counts" is at the heart of the strategy of the group: Tessenderlo Group continually strives to valorise its products and processes to the maximum and to add value to everything it does. In 2025, Tessenderlo Group recorded a consolidated revenue of 2.8 billion EUR. Tessenderlo Group is listed on Euronext Brussels and is part of the Next 150 and BEL Mid indices. Financial News wires: Bloomberg: TESB BB - Reuters: TESB.BR - Datastream: B:Tes. For more information about Tessenderlo Group, its people, its brands, and its results, please visit www.tessenderlo.com.

FMC Disclaimer
Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:  FMC and its representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, information regarding the proposed transaction, the ability to negotiate a leaseback agreement, any impact on FMC's research operations, and the expected timing of and proceeds from the proposed transaction.

In some cases, FMC has identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement, including risks relating to the proposed transaction and the risk that the proposed transaction is not successfully completed. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaims any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

Tessenderlo Group Disclaimer
This document may contain forward-looking statements. Such statements reflect the views of management regarding future events at the date of this document. Furthermore, they involve known and unknown risks, uncertainties and other factors that may cause actual results to be different from any results, performance or achievements expressed or implied by such forward-looking statements. Tessenderlo Group provides the information in this press release as at the date of publication and, subject to applicable legislation, does not undertake any obligation to update, clarify or correct any forward-looking statements contained in this press release in light of new information, future events or otherwise. Tessenderlo Group disclaims any liability for statements made or published by third parties (including any employees who are not explicitly mandated by Tessenderlo Group) and, subject to applicable legislation, does not undertake any obligation to correct inaccurate data, information, conclusions or opinions published by third parties in relation to this or any other press release it issues.

SOURCE FMC Corporation

Company will continue to operate its global R&D headquarters at the Stine Research Center

, /PRNewswire/ --

FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, today announced that it has entered into a framework agreement to sell its property in Newark, Delaware for gross proceeds of approximately $114 million USD, subject to a due diligence period and other closing conditions and adjustments. Upon completion of the sale, FMC intends to lease back the facilities it actively operates under a separate lease agreement. FMC will retain ownership of its adjacent Maryland properties.

The decision to pursue this transaction reflects FMC's ongoing efforts to optimize its asset base, converting underutilized real estate into capital that will be applied directly to debt reduction while maintaining the operational capabilities central to the company's growth strategy.

The transaction is structured to minimize any disruption to FMC's research operations. FMC's Stine Research Center, its global R&D headquarters, will continue to operate at the site following the transaction. The company's R&D capabilities, core research activities and scientific infrastructure remain fully in place.

"The Stine Research Center remains the global headquarters for FMC's R&D organization and will continue to play a central role in advancing our innovation pipeline," said Seva Rostovtsev, executive vice president and chief technology officer. "This transaction allows us to optimize our physical footprint by reducing underutilized space while preserving and improving the world-class facilities, infrastructure and scientific talent that power our research and long-term growth."

"Unlocking the value of underutilized real estate and applying the proceeds to debt reduction reflects our ongoing commitment to strengthening our balance sheet without compromising the investments and capabilities that will drive FMC's future growth," said Andrew Sandifer, executive vice president and chief financial officer.

The transaction is expected to close in the fourth quarter of 2026, subject to a due diligence period and various other closing conditions and adjustments. As is customary for transactions of this kind, the parties may elect to renegotiate certain terms during the diligence period and to amend the framework agreement accordingly. The agreement also contemplates that the form of the leaseback agreement and various other operational and economic terms are still to be agreed between the parties and are therefore at a preliminary stage. As a result, there can be no assurance that the framework agreement will ultimately result in any transaction.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:  FMC and its representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, regarding the agreement, the ability to negotiate a leaseback agreement, any impact on FMC's research operations, and the expected timing of and proceeds from the transaction.

In some cases, FMC has identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaims any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

SOURCE FMC Corporation

FMC Corporation (FMC) Presents at 3rd Annual Materials of the Future Conference Transcript

Strategic supply and license agreement will accelerate access for North and South American corn and soybean growers

, /PRNewswire/ -- FMC Corporation (NYSE: FMC) and Corteva, Inc. (NYSE: CTVA), two leading global agricultural science and innovation companies, today announced a co-exclusive strategic supply and license agreement that will expand access to FMC's rimisoxafen technology across North and South America corn and soybean markets, adding an important new tool to each company's respective herbicide portfolio. This collaboration will enable more growers across the Americas to control herbicide-resistant weeds, including Amaranthus species – the number one weed resistance challenge globally in soybeans and critical in cross-crop pressure in corn – with this groundbreaking dual mode of action herbicide technology.

"This agreement ensures that more growers across the Americas will have access to rimisoxafen, one of the most innovative herbicide technologies developed in decades," said Leonardo Bastos, FMC vice president and chief marketing officer. "By working with Corteva, we are expanding the reach of this breakthrough technology to help growers effectively manage resistant weeds that threaten their productivity and profitability. Together, we are bringing growers a solution they urgently need. At the same time, FMC is committed to unlocking the full global potential of rimisoxafen across additional crops and geographies, reflecting our confidence in this molecule as a cornerstone of our innovation pipeline."

Under the terms of the agreement, which extends through the next decade, FMC retains all rights of ownership to rimisoxafen and will supply Corteva with the active ingredient. Both companies will develop and commercialize their own exclusive premix formulations for the corn and soybean markets across North and South America, while FMC will continue to develop additional rimisoxafen-based products for other crops and geographies globally. Corteva will make an initial prepurchase payment of $200 million USD for product to be supplied by FMC. Together, both companies are committed to ensuring broad availability of this innovative technology and rapid adoption, supporting growers with durable weed management solutions for years to come.

"By collaborating with FMC on rimisoxafen, we are expanding our ability to provide growers with advanced weed control tools that complement our portfolio," said Cynthia Ericson, Corteva vice president, weed control segment. "This agreement supports our long-term strategy of forging new collaborations that drive value for farmers, as well as a unique growth opportunity with attractive economics for Corteva above our current deep crop protection pipeline set to launch over the next decade."

Rimisoxafen's dual mode of action creates a significantly higher barrier to resistance development compared to single mode of action herbicides, providing growers with an essential tool for managing weeds like palmer amaranth and waterhemp that have become resistant to multiple herbicide classes and cost farmers billions of dollars annually in lost yield. First commercial sales are anticipated by the end of the decade, pending applicable regulatory approvals. The Herbicide Resistance Action Committee recently classified rimisoxafen as the industry's first dual mode of action herbicide, recognizing its unique ability to control troublesome broadleaf weeds that threaten crop yields and farm profitability.

Additional terms of the agreement were not disclosed.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

About Corteva
Corteva, Inc. (NYSE: CTVA) is a global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world's most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the Company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at www.corteva.com.

Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:  FMC, Corteva and their respective representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, in each company's other filings with the SEC, and in presentations, reports or letters to their stockholders.

In some cases, the companies identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on the companies' current views and assumptions regarding future events, future business conditions and the outlook for the companies based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of each company's Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaim any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

SOURCE FMC Corporation

NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Alpha FMC (“Alpha”), a leading global consultancy to the financial services industry, today announces the appointment of Zoe Kohli as Senior Partner, Global Partner Executive in its Asset & Wealth Management practice.

Zoe rejoins Alpha following senior roles at two of the world’s largest investment technology providers, where she led product, strategy, and commercial functions. She brings extensive experience at the intersection of technology and business strategy, helping clients deliver measurable outcomes through large-scale transformation programmes. She will continue to advise clients on their most complex and strategic initiatives.

In her role as Global Partner Executive, Zoe will be accountable for defining, driving, and managing Alpha’s relationship with SimCorp. She will focus on enhancing Alpha’s capabilities, driving partner value-creation initiatives, and coordinating with regional teams to deliver the full scope of Alpha’s offering to shared clients. 

Joe Morant, Global Head of Asset & Wealth Management said:

“We are delighted to welcome Zoe back to Alpha at an important time for both our clients and our business. Over recent years, an increasing number of clients have selected Alpha as the delivery partner for their mission-critical investment platform initiatives. With the appointment of Zoe, the acquisition of JPSB, and investment in the wider Alpha team, we are poised for accelerated growth. We look forward to continuing to assist both new and existing clients in navigating and delivering their evolve-and-transform priorities using the SimCorp platform.”

Zoe Kohli, Senior Partner added:

“It’s fantastic to be returning to Alpha FMC. Having spent time both within Alpha and across the broader ecosystem, I’ve seen firsthand the strength of the firm’s expertise and the trust it has built with clients. Alpha stands apart in its ability to combine deep domain expertise with true global scale. I’m excited to play a role in accelerating Alpha’s continued growth and reinforcing its leadership position in the sector.”

About Alpha FMC

Alpha Financial Markets Consulting is a leading global consultancy to the financial services industry. Alpha combines highly specialist sector-focused strategy, management consulting and technology expertise to support the client transformation lifecycle. Founded in 2003, it now has over 1,540 consultants across North America, UK, Europe, MENA and APAC. Alpha has been supported by investment partner Bridgepoint, one of the world’s leading quoted private asset growth investors, since 2024.

Wall Street expects a year-over-year decline in earnings on lower revenues when FMC (FMC - Free Report) reports results for the quarter ended March 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 29. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis chemical producer is expected to post quarterly loss of $0.39 per share in its upcoming report, which represents a year-over-year change of -316.7%.

Revenues are expected to be $721.81 million, down 8.8% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for FMC?For FMC, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +2.06%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination indicates that FMC will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that FMC would post earnings of $1.21 per share when it actually produced earnings of $1.20, delivering a surprise of -0.83%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

FMC appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Company continues to advance operational priorities and explore strategic options in parallel

First Quarter 2026 Highlights

Revenue of $759 million, down 4 percent versus Q1 2025 Revenue excluding India1 of $762 million, down 4 percent versus Q1 2025 (which included India) Organic revenue2 for the period declined 9 percent Consolidated GAAP net loss of $281 million, a decline of $266 million versus Q1 2025 Adjusted EBITDA of $72 million, down 40 percent versus Q1 2025 Consolidated GAAP loss of $2.25 per diluted share, down $2.13 versus Q1 2025 Adjusted loss per diluted share of $0.23, down 41 cents versus Q1 2025 Maintains 2026 Full-Year Outlook1

Revenue excluding India of $3.60 billion to $3.80 billion, a decline of 5 percent at the midpoint versus 2025 Excluding 2025 India contributions, the 2026 outlook represents a decline at the midpoint of 3 percent Adjusted EBITDA of $670 million to $730 million, a decline of 17 percent at the midpoint Adjusted earnings per diluted share of $1.63 to $1.89, a decline of 41 percent at the midpoint Free cash flow of negative $65 million to $65 million, an improvement of $165 million at the midpoint , /PRNewswire/ -- FMC Corporation (NYSE:FMC) today reported first quarter 2026 revenue of $759 million, down 4 percent versus first quarter 2025.  First quarter 2026 revenue, excluding India, was $762 million, down 4 percent versus first quarter 2025, which included India.  On a GAAP basis, the company reported a loss of $2.25 per diluted share in the first quarter, a decrease of $2.13 versus first quarter 2025.  First quarter adjusted loss per diluted share of $0.23 was down 41 cents versus first quarter 2025.

FMC Revenue

Q1 2026

Total Revenue Change (GAAP)

(4) %

Total Revenue Change (ex-India) (Non-GAAP)

(4) %

Less: 2025 revenue for India held for sale business

(5) %

Like-for-Like Revenue Change (Non-GAAP)

1 %

First quarter sales of $762 million, excluding India, were above the midpoint of guidance and 4 percent lower than the prior year. The removal of India represented a 5 percent sales headwind. Price declined 6 percent, in line with expectations, driven by lower pricing to diamide partners, pricing actions on branded Rynaxypyr® products and a competitive market for legacy core products – particularly in Latin America. Foreign currency was a tailwind of 5 percent. Volume improved 2 percent, driven by strong growth in EMEA and North America. New active ingredient sales doubled year-over-year. Plant Health grew 6 percent.

FMC Regional Revenue ($M)

Q1 2026

Q1 2025

North America

$198

$186

Latin America

$177

$207

EMEA

$307

$273

Asia (excluding 2026 India)1

$81

$125

2026 India1

$(4)

—

Total Revenue (GAAP)

$759

$791

Note: Regional results ex. India sum to $763M due to rounding

GAAP net loss in the first quarter declined $266 million primarily due to tax charges related to an increase in valuation allowances. Lower sales, higher restructuring costs and higher interest expense also contributed to the loss during the first quarter. FMC first quarter Adjusted EBITDA was $72 million, a decrease of 40 percent from the prior-year period, driven by lower pricing and unfavorable costs. The cost increase was driven by tariffs as well as unfavorable raw material costs.

On a GAAP basis, cash from operations was negative $601 million, a decline of $56 million versus 2025, primarily driven by lower Adjusted EBITDA.  Free cash flow was negative $628 million, a decline of $32 million versus Q1 2025 primarily due to lower cash from operations, partially offset by lower capital expenditures.

Strategy Update

FMC is making strong progress on its 2026 operational priorities, which are strengthening the balance sheet through targeted debt reduction of approximately $1 billion, improving the competitiveness of its core portfolio, managing the post-patent transition for Rynaxypyr® active, and driving growth of new active ingredients including Isoflex® active, fluindapyr and Dodhylex® active. In parallel, the Board-authorized evaluation of strategic alternatives announced in February 2026 is progressing, and multiple options are being evaluated. There can be no assurance that the process will result in any transaction. The company does not intend to comment further at this time, except as it may do so in the ordinary course in connection with its upcoming earnings call, or if it determines that further disclosure is appropriate or necessary.

Full Year Outlook1

The company reaffirms its full-year 2026 revenue, Adjusted EBITDA, Adjusted EPS and free cash flow guidance ranges.  Full year 2026 revenue guidance1 is $3.60 billion to $3.80 billion, a decline of 5 percent at the midpoint versus prior year1. Price is expected to be lower by mid-single digits mainly due to Rynaxypyr® active, which is consistent with the company's post-patent strategy. Excluding India, volume is expected to be up modestly as increases in branded Rynaxypyr® active and new active ingredients are largely offset by reduced diamide partner orders and declines in the legacy core portfolio. India represents a 2 percent headwind1. FX is expected to be neutral. Sales of new active ingredients are expected to be between $300 million and $400 million, representing growth of over 75 percent at the midpoint versus prior year.

Adjusted EBITDA is expected to be $670 million to $730 million, a decline of 17 percent versus prior year as lower price and an FX headwind are partially offset by volume growth and favorable costs. EPS is expected to be $1.63 to $1.89, a decrease of 41 percent versus prior year, primarily due to lower Adjusted EBITDA and, to a lesser extent, increased interest expense. Free cash flow is expected to be negative $65 million to $65 million.

Second Quarter and H2 Outlook1

Second quarter revenue is expected to be in the range of $850 million to $900 million, a decline of 17 percent at the midpoint compared to second quarter 2025, primarily due to lower volume to diamide partners and the removal of India. The India inclusion in prior year represents a 5 percent headwind.  Price is expected to decline mid-single digits due to competitive pressure and planned pricing actions for Rynaxypyr® in line with the post-patent strategy. FX is expected to be a low-single digit tailwind. Adjusted EBITDA is forecasted to be in the range of $130 million to $150 million, a decline of 32 percent versus the prior year as lower sales are partially offset by favorable costs. FMC expects Adjusted EPS to be in the range of $0.16 to $0.26 in the second quarter, which represents a 70 percent decrease at the midpoint versus second quarter 2025, due to lower Adjusted EBITDA as well as higher interest expense to a lesser degree.

The midpoint of first-half guidance implies a second-half sales increase of 1 percent versus prior year. Price is expected to be a mid-single digit headwind, driven by competitive market conditions for core portfolio products and pricing actions to support the branded Rynaxypyr® active strategy. Lower price and a minor FX headwind are expected to be more than offset by volume growth, driven primarily by increased sales of products with new active ingredients.

Second-half Adjusted EBITDA is expected to decrease 6 percent as lower price and a minor FX headwind are partially offset by higher volume and favorable costs. Second-half Adjusted EPS is expected to decline 15 percent compared to second half 2025, due to lower Adjusted EBITDA, higher tax, and higher interest expense.

Full-Year 2026
Outlook1

 Q2 2025
Outlook1

First-Half
Outlook1

Second-Half
Outlook1

Revenue Excl.
India

$3.60 billion to

$3.80 billion

$850 million to

$900 million

$1.61 billion to

$1.66 billion

$1.99 billion to

$2.14 billion

Growth at midpoint
vs. 2025*

(5) %

(17) %

(11) %

1 %

Adjusted
EBITDA

$670 million to

$730 million

$130 million to

$150 million

$202 million to

$222 million

$468 million to

$508 million

Growth at midpoint
vs. 2025*

(17) %

(32) %

(35) %

(6) %

Adjusted
EPS^

$1.63 to $1.89

$0.16 to $0.26

$(0.07) to $0.03

$1.70 to $1.86

Growth at midpoint
vs. 2025*

(41) %

(70) %

(102) %

(15) %

^ EPS estimates assume 125.9 million diluted shares for full year, Q2 and H2; 125.3 million diluted shares for H1. 

*Percentages are calculated using whole numbers.  Minor differences may exist due to rounding.  India excluded from 2026 guidance and H2 2025 actuals.  Variances are calculated versus 2025 results, which include India in the first half of the year.

Supplemental Information

The company will post supplemental information on the web at https://investors.fmc.com, including its webcast slides for tomorrow's earnings call, definitions of non-GAAP terms and reconciliations of non-GAAP figures to the nearest available GAAP term.

Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions. FMC and the FMC logo are trademarks of FMC Corporation or an affiliate.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:  FMC and its representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, in FMC's other filings with the SEC, and in presentations, reports or letters to FMC stockholders.

In some cases, FMC has identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaim any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

This press release contains certain "non-GAAP financial terms" which are defined on our website www.fmc.com/investors. Such terms include Adjusted EBITDA, Adjusted earnings, free cash flow and organic revenue growth. In addition, we have also provided on our website reconciliations of non-GAAP terms to the most directly comparable GAAP terms.

Although we provide forecasts for adjusted earnings per share, Adjusted EBITDA, and free cash flow (non-GAAP financial measures), we are not able to forecast the most directly comparable measures calculated and presented in accordance with GAAP. Certain elements of the composition of the GAAP amounts are not predictable, making it impractical for us to forecast. Such elements include, but are not limited to, restructuring, acquisition charges, our India held for sale business, and discontinued operations. As a result, no GAAP outlook is provided. Starting with the third quarter 2025 guidance, we provide forecasts for revenue excluding India (non-GAAP financial measure). We are not able to forecast the GAAP revenue due to potential actions we may take during the held for sale period to prepare the business for a potential buyer and other uncertainties, including customer reaction to the announcement of our intention to sell our India commercial business. In 2026, revenue, Adjusted EBITDA and Adjusted EPS outlooks provided exclude India results and variances are calculated versus 2025 results, which include India results in the first half of the year.  Organic revenue growth (non-GAAP) excludes the impact of foreign currency changes and the removal of India. FMC CORPORATION

CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(Unaudited)

Three Months Ended March 31,

(In millions, except per share amounts)

2026

2025

Revenue

$          758.6

$           791.4

Costs of sales and services

512.0

474.7

Gross margin

$          246.6

$           316.7

Selling, general and administrative expenses

185.1

172.0

Research and development expenses

65.5

68.7

Restructuring and other charges (income)

77.0

17.8

Total costs and expenses

$          839.6

$           733.2

Income from continuing operations before non-operating pension, postretirement, and
other charges (income), interest expense, net and income taxes

$           (81.0)

$             58.2

Non-operating pension, postretirement, and other charges (income)

3.4

3.2

Interest expense, net

64.8

50.1

Income (loss) from continuing operations before income taxes

$         (149.2)

$               4.9

Provision (benefit) for income taxes

112.1

13.5

Income (loss) from continuing operations

$         (261.3)

$              (8.6)

Discontinued operations, net of income taxes

(19.9)

(7.0)

Net income (loss)

$         (281.2)

$            (15.6)

Less: Net income (loss) attributable to noncontrolling interests

0.1

(0.1)

Net income (loss) attributable to FMC stockholders

$         (281.3)

$            (15.5)

Amounts attributable to FMC stockholders:

  Income (loss) from continuing operations, net of tax

$         (261.4)

$              (8.5)

  Discontinued operations, net of tax

(19.9)

(7.0)

  Net income (loss)

$         (281.3)

$            (15.5)

Basic earnings (loss) per common share attributable to FMC stockholders:

  Continuing operations

$           (2.09)

$            (0.06)

  Discontinued operations

(0.16)

(0.06)

  Basic earnings per common share

$           (2.25)

$            (0.12)

Average number of shares outstanding used in basic earnings per share computations

125.3

125.1

Diluted earnings (loss) per common share attributable to FMC stockholders:

  Continuing operations

$           (2.09)

$            (0.06)

  Discontinued operations

(0.16)

(0.06)

  Diluted earnings per common share

$           (2.25)

$            (0.12)

Average number of shares outstanding used in diluted earnings per share computations

125.3

125.1

Other Data:

Capital additions and other investing activities

$            15.8

$             37.4

Depreciation and amortization expense

$            42.0

$             43.7

FMC CORPORATION

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

RECONCILIATION OF NET INCOME (LOSS) ATTRIBUTABLE TO FMC STOCKHOLDERS (GAAP) TO
ADJUSTED AFTER-TAX EARNINGS FROM CONTINUING OPERATIONS, ATTRIBUTABLE TO FMC
STOCKHOLDERS (NON-GAAP) (1)

(Unaudited)

Three Months Ended March 31,

(In millions, except per share amounts)

2026

2025

Net income (loss) attributable to FMC stockholders (GAAP)

$         (281.3)

$           (15.5)

Corporate special charges (income):

Restructuring and other charges (income) (a)

94.7

17.8

Non-operating pension, postretirement, and other charges (income) (b)

3.4

3.2

India held for sale business (c)

16.4

—

Income tax expense (benefit) on Corporate special charges (income) (d)

(18.3)

(4.4)

Discontinued operations attributable to FMC stockholders, net of income taxes (e)

19.9

7.0

Tax adjustment (f)

136.3

14.3

Adjusted after-tax earnings (loss) from continuing operations attributable to FMC
stockholders (non-GAAP) (1)

$           (28.9)

$             22.4

Diluted earnings (loss) per common share (GAAP)

$           (2.25)

$           (0.12)

Corporate special charges (income) per diluted share, before tax:

Restructuring and other charges (income)

0.76

0.14

Non-operating pension, postretirement, and other charges (income)

0.03

0.03

India held for sale business

0.13

—

Income tax expense (benefit) on Corporate special charges (income), per diluted share

(0.15)

(0.04)

Discontinued operations attributable to FMC stockholders, net of income taxes per diluted share 

0.16

0.06

Tax adjustments per diluted share

1.09

0.11

Diluted adjusted after-tax earnings (loss) from continuing operations per share,
attributable to FMC stockholders (non-GAAP)

$           (0.23)

$             0.18

Average number of shares outstanding used in diluted adjusted after-tax earnings (loss) from
continuing operations per share computations

125.3

125.5

(1)

Referred to as Adjusted earnings. The Company believes that Adjusted earnings, a non-GAAP financial measure, and its presentation on a per share basis provides useful information about the Company's operating results to management, investors, and securities analysts. Adjusted earnings excludes the effects of corporate special charges, the India held for sale business, tax-related adjustments and the results of our discontinued operations. The Company also believes that excluding the effects of these items from operating results allows management and investors to compare more easily the financial performance of its underlying business from period to period.

(a)

Three Months Ended March 31, 2026:

Restructuring and other charges (income) includes restructuring charges of $94.5 million primarily comprised of $90.1 million in charges related to Project Foundation, which is management's comprehensive plan to further optimize FMC's cost structure and organizational operations. The charges for Project Foundation include non-cash asset write-off and accelerated depreciation costs of $64.7 million primarily associated with the planned exit of certain production activities; severance and employee separation costs of $6.2 million; and, other miscellaneous charges of $19.2 million, which include contract exit costs and professional service provider costs. During the three months ended March 31, 2026, we also recorded Project Focus-related costs of $4.3 million, primarily related to miscellaneous charges associated with previously implemented activities. Other charges (income) included $3.9 million of charges associated with our environmental sites and $3.7 million of other miscellaneous income.

Three Months Ended March 31, 2025:

Restructuring and other charges (income) includes restructuring charges of $13.6 million primarily related Project Focus, which included $6.6 million of professional service provider costs and other miscellaneous charges, $4.2 million of severance and employee separation costs, and accelerated depreciation of $3.1 million on assets identified for disposal in connection with the restructuring initiative. Other charges (income) of $4.2 million is comprised of $3.5 million of charges associated with our environmental sites and $0.7 million of other miscellaneous charges.

(b)

Our non-operating pension, postretirement and other charges (income) includes those costs (benefits) related to interest, expected return on plan assets, amortized actuarial gains and losses and the impacts of any plan curtailments or settlements. These are excluded from our Adjusted earnings and are primarily related to changes in pension plan assets and liabilities which are tied to financial market performance and we consider these costs to be outside our operational performance. We continue to include the service cost and amortization of prior service cost in our Adjusted earnings results noted above. These elements reflect the current year operating costs to our businesses for the employment benefits provided to active employees.  

(c)

In July 2025, the Board of Directors approved a plan to divest the Company's commercial business in India in response to ongoing challenges in the country. The sale process is underway and is expected to conclude during 2026; and, therefore, the assets related to this business have been classified as held for sale since the third quarter of 2025. The business does not qualify for recognition as discontinued operations and will continue to be presented in the Company's reported GAAP results until a transaction is completed. Beginning with the third quarter of 2025, we have excluded the impact of various activities associated with the anticipated sale from our operating results for non-GAAP purposes. Refer to the table below for the adjustments related to the India held for sale business for the three months ended March 31, 2026.

Three Months Ended March 31,

Affected Line Item in the Consolidated
Statements of Income (Loss)

(In millions)

2026

2025

Operating results

$               34.1

$                  —

Revenue, Cost of sales and services, and
Selling, general and administrative expenses

Asset impairment

(20.4)

—

Restructuring and other charges (income)

Third party provider costs

2.7

—

Restructuring and other charges (income)

India held for sale business

$               16.4

$                  —

(d)

The income tax expense (benefit) on Corporate special charges (income) is determined using the applicable rates in the taxing jurisdictions in which the corporate special charge or income occurred and includes both current and deferred income tax expense (benefit) based on the nature of the non-GAAP performance measure.

(e)

Discontinued operations includes provisions, net of recoveries, for environmental liabilities and legal reserves and expenses related to previously discontinued operations and retained liabilities.

(f)

We exclude the GAAP tax provision, including discrete items, from the non-GAAP measure of income, and include a non-GAAP tax provision based upon the projected annual non-GAAP effective tax rate. The GAAP tax provision includes certain discrete tax items including, but are not limited to: income tax expenses or benefits that are not related to continuing operating results in the current year; tax adjustments associated with fluctuations in foreign currency remeasurement of certain foreign operations; certain changes in estimates of tax matters related to prior fiscal years; certain changes in the realizability of deferred tax assets and related interim accounting impacts; and changes in tax law. In 2024 and 2023, we recorded significant deferred tax assets due to various tax incentives granted to the Company's Swiss subsidiaries (the "Swiss Tax Incentives"). The initial recognition of these Swiss Tax Incentives did not impact our adjusted non-GAAP effective tax rate but will be considered annually as we realize the benefits. Management believes excluding these discrete tax items, as well as the impacts of the Swiss Tax Incentives annually as the related benefits are realized, assists investors and securities analysts in understanding the tax provision and the effective tax rate related to continuing operating results thereby providing investors with useful supplemental information about FMC's operational performance.

Three Months Ended March 31,

(In millions)

2026

2025

Tax adjustments:

Revisions to valuation allowances of historical deferred tax assets (i)

$             124.7

$               (1.2)

Net impact of Switzerland tax incentives

(5.5)

2.8

Foreign currency remeasurement and other discrete items

17.1

12.7

Total non-GAAP tax adjustments

$             136.3

$               14.3

(i)

As a result of changes in global earnings mix and ongoing tax planning implemented in March 2026, we reevaluated the realizability of our historical deferred tax assets and recorded an increase to our valuation allowance in Switzerland of approximately $123 million during the three months ended March 31, 2026.

RECONCILIATION OF NET INCOME (LOSS) (GAAP) TO ADJUSTED EARNINGS FROM CONTINUING
OPERATIONS, BEFORE INTEREST, INCOME TAXES, DEPRECIATION AND AMORTIZATION, AND
NONCONTROLLING INTERESTS (NON-GAAP) (3)

(Unaudited)

Three Months Ended March 31,

(In millions)

2026

2025

Net income (loss) (GAAP)

$         (281.2)

$           (15.6)

Restructuring and other charges (income) (1)

94.7

17.8

Non-operating pension, postretirement, and other charges (income)

3.4

3.2

India held for sale business (2)

16.4

—

Discontinued operations, net of income taxes

19.9

7.0

Interest expense, net

64.8

50.1

Depreciation and amortization

42.0

43.7

Provision (benefit) for income taxes

112.1

13.5

Adjusted earnings from continuing operations, before interest, income taxes, depreciation
and amortization, and noncontrolling interests (non-GAAP) (3)

$             72.1

$           119.7

(1)

In the reconciliation above, favorable adjustments recorded in connection with the India held for sale business of $17.7 million for the three ended March 31, 2026 are presented in the India held for sale business line, as described in the reconciliation in note (c) above. On the consolidated statements of income (loss), these adjustments are recorded to "Restructuring and other charges (income)."

(2)

Beginning with the third quarter of 2025, we excluded the operating results of the India commercial business during the held for sale period for non-GAAP purposes. For further details on the charges and write-downs recorded in connection with the India held for sale business, refer to note (c) in the reconciliation above.

(3)

Referred to as Adjusted EBITDA. Defined as operating profit excluding restructuring and other charges (income), depreciation and amortization expense, and the India held for sale business.

RECONCILIATION OF CASH PROVIDED (REQUIRED) BY OPERATING ACTIVITIES OF CONTINUING
OPERATIONS (GAAP) TO FREE CASH FLOW (NON-GAAP) (2)

(Unaudited)

Three Months Ended March 31,

(In millions)

2026

2025

Cash provided (required) by operating activities of continuing operations (GAAP) (1)

$          (600.9)

$          (545.0)

Capital expenditures

(16.6)

(31.6)

Other investing activities

0.8

(5.8)

Capital additions and other investing activities

$            (15.8)

$            (37.4)

Cash provided (required) by operating activities of discontinued operations

(15.7)

(13.3)

Divestiture transaction costs (2)

4.3

—

Free cash flow (non-GAAP) (3)

$          (628.1)

$          (595.7)

(1)

The three months ended March 31, 2026 includes cash payments of $66.4 million primarily for restructuring activities related to the Project Focus transformation program as well as Project Foundation. The three months ended March 31, 2025 includes cash payments of $55.7 million for Project Focus.

(2)

Represents third party provider costs associated with the expected sale of our India commercial business. Proceeds from the sale of our India commercial business anticipated in 2026 will be excluded from free cash flow when received. Therefore, we have also excluded the related transaction costs from free cash flow.

(3)

Free cash flow is defined as cash provided (required) by operating activities of continuing operations (GAAP) adjusted for spending for capital additions and other investing activities as well as cash provided (required) by discontinued operations and divestiture transaction costs associated with the sale of our GSS business. We believe that this non-GAAP financial measure provides a useful basis for investors and securities analysts to evaluate the cash generated by routine business operations, including to assess our ability to repay debt, fund acquisitions and return capital to shareholders through share repurchases and dividends. Our use of free cash flow has limitations as an analytical tool and should not be considered in isolation or as a substitute for an analysis of our results under U.S. GAAP.

RECONCILIATION OF REVENUE (GAAP)

TO REVENUE EXCLUDING INDIA (NON-GAAP) (2)

(Unaudited)

Three Months Ended March 31,

(In millions)

2026

2025

Revenue (GAAP)

$               758.6

$               791.4

Less: Revenue from India commercial business (1)

(3.8)

—

Revenue excluding India (non-GAAP) (2)

$               762.4

$               791.4

(1)

Beginning with the third quarter of 2025, revenue from the India commercial business is excluded from our adjusted results during the held for sale period for non-GAAP purposes. Refer to note (c) above for further details.

(2)

Although the India held for sale business does not qualify for recognition as discontinued operations, we believe Revenue excluding India (non-GAAP) provides management and investors with useful supplemental information regarding our ongoing revenue performance.

RECONCILIATION OF REVENUE CHANGE (GAAP) TO 
ORGANIC REVENUE CHANGE (NON-GAAP) (1)

(Unaudited)

Three Months Ended March 31, 2026 vs. 2025

Total revenue (GAAP) change

(4) %

Less: Revenue for India held for sale business for the three months ended
March 31, 2026

— %

Revenue excluding India (non-GAAP) change (1)

(4) %

Less:  Foreign currency impact

5 %

Organic revenue (non-GAAP) change (2)

(9) %

(1)

Beginning with the third quarter of 2025, revenue from the India commercial business is excluded from our adjusted results during the held for sale period for non-GAAP purposes. Refer to note (c) above for further details.

(2)

We believe organic revenue growth (non-GAAP) provides management and investors with useful supplemental information regarding our ongoing revenue performance and trends by presenting revenue growth excluding the impact of fluctuations in foreign exchange rates and the India held for sale business.

RECONCILIATION OF NET INCOME (LOSS) ATTRIBUTABLE TO

FMC STOCKHOLDERS (GAAP) TO RETURN ON INVESTED CAPITAL ("ROIC")

NUMERATOR (NON-GAAP) AND ADJUSTED ROIC (USING NON-GAAP NUMERATOR) (1)

(Unaudited)

Twelve Months Ended

(In millions, except percentages)

March 31, 2026

Net income (loss) attributable to FMC stockholders (GAAP)

$                     (2,504.7)

Interest expense, net, net of income taxes

218.7

Corporate special charges (income)

1,871.5

India held for sale business

538.1

Income tax expense (benefit) on Corporate special charges (income)

(172.0)

Discontinued operations attributable to FMC stockholders, net of income
taxes

49.5

Tax adjustments

538.3

ROIC numerator (non-GAAP)

$                          539.4

March 31, 2026

March 31, 2025

Total debt

$                       4,533.6

$                          4,003.5

Total FMC stockholders' equity

1,822.1

4,382.0

Total debt and FMC stockholders' equity (GAAP)

$                       6,355.7

$                          8,385.5

ROIC denominator (2 yr average total debt and FMC stockholders' equity)

$                       7,370.6

ROIC (using Net income (loss) attributable to FMC stockholders (GAAP)
as numerator)

(33.98) %

Adjusted ROIC (using non-GAAP numerator) (1)

7.32 %

(1)

We believe Adjusted ROIC (non-GAAP) provides management and investors with useful supplemental information regarding our utilization of capital provided by both equity and debt as well as our working capital and free cash flow management. Additionally, vesting of certain restricted stock awards granted to officers is connected to Adjusted ROIC as a performance metric.

FMC CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In millions)

March 31, 2026

December 31, 2025

Cash and cash equivalents

$                 390.9

$                 584.5

Trade receivables, net of allowance of $42.5 in 2026 and $43.3 in 2025

2,244.8

2,062.0

Inventories

1,242.6

1,219.6

Prepaid and other current assets

533.7

481.2

Assets held for sale (1)

492.9

611.7

Total current assets

$              4,904.9

$              4,959.0

Property, plant and equipment, net

627.5

707.4

Other intangibles, net

2,333.5

2,361.8

Deferred income taxes

1,096.0

1,215.6

Other long-term assets

457.6

443.4

Total assets

$              9,419.5

$              9,687.2

Short-term debt and current portion of long-term debt

$              1,763.0

$              1,305.1

Accounts payable, trade and other

634.1

771.0

Advanced payments from customers

196.3

453.1

Accrued and other liabilities

625.5

574.0

Accrued customer rebates

480.0

417.4

Guarantees of vendor financing

37.0

45.7

Accrued pensions and other postretirement benefits, current

3.3

3.3

Income taxes

26.6

24.0

Liabilities held for sale (1)

47.5

161.7

Total current liabilities

$              3,813.3

$              3,755.3

Long-term debt, less current portion

$              2,770.6

$              2,769.8

Long-term liabilities

985.7

1,063.2

Equity

1,849.9

2,098.9

Total liabilities and equity

$              9,419.5

$              9,687.2

(1)

The carrying value of the India held for sale business decreased from $450 million as of December 31, 2025 to $425.0 million as of March 31, 2026 primarily due to receivable collections during the period. The carrying value of the held for sale business is comprised of $445.4 million of net assets held for sale as presented on the consolidated balance sheet and a gain of 20.4 million related to foreign currency translation in connection with the assets identified for disposal. The foreign currency translation gains are recorded in "Accumulated other comprehensive income (loss)" on the consolidated balance sheet and will be reclassified to the consolidated statement of income (loss) upon close of the sale.

FMC CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Three Months Ended March 31,

(In millions)

2026

2025

Cash provided (required) by operating activities of continuing operations

$                (600.9)

$                (545.0)

Cash provided (required) by operating activities of discontinued operations

(15.7)

(13.3)

Cash provided (required) by investing activities of continuing operations

(16.2)

(38.0)

Cash provided (required) by financing activities of continuing operations

442.3

552.1

Effect of exchange rate changes on cash

(3.1)

2.2

Increase (decrease) in cash and cash equivalents

$                (193.6)

$                  (42.0)

Cash and cash equivalents, beginning of period

$                 584.5

$                 357.3

Cash and cash equivalents, end of period

$                 390.9

$                 315.3

SOURCE FMC Corporation

Key Takeaways FMC Q1 revenues fell 4% to $759M but topped estimates; adjusted loss of 23 cents beat forecasts.FMC saw sales growth in North America and EMEA, while Latin America and Asia ex-India declined.FMC reaffirmed 2026 outlook and sees Q2 revenues excluding India of $850M-$900M. FMC Corporation (FMC - Free Report) reported a first-quarter 2026 adjusted loss per share of 23 cents. This compares unfavorably to the year-ago quarter’s adjusted earnings per share of 18 cents. The result was narrower than the Zacks Consensus Estimate of a loss of 39 cents.

Quarterly revenues of $759 million declined 4% year over year but topped the consensus estimate of $721.8 million by 5.2%. Performance reflected favorable currency and stronger demand in select markets, partly offset by pricing pressure and partner-related volume headwinds. New active ingredient sales doubled year over year.

Profitability also declined as lower pricing and higher costs more than offset benefits from volume and currency. Tariffs and unfavorable raw material costs were the key cost headwinds, while lower R&D expenses provided some relief. The decline was also driven by tax charges related to higher valuation allowances, along with lower sales, higher restructuring costs and higher interest expense.

FMC’s Regional Sales PerformanceNorth America sales increased 6% year over year to $198 million. FMC attributed the gain to high-teens sales growth for branded products led by herbicides, alongside solid growth in Plant Health and strong Cyazypyr performance. Sales topped the consensus estimate of $185.1 million.

EMEA revenues rose 13% to $307 million on solid branded volume growth led by herbicides and Cyazypyr. Branded pricing was similar to the year-ago quarter, while registration losses were in line with expectations and represented an estimated 5% headwind. It outpaced the consensus estimate of $282.4 million.

Latin America revenues fell 14% to $177 million. FMC cited lower branded volumes mainly for core portfolio products and a competitive market for core products that pressured branded pricing, though higher growth-portfolio sales led by Cyazypyr and new actives provided a partial offset. It missed the consensus estimate of $178.7 million.

Asia revenues, excluding India, declined 36% year over year to $81 million. The company pointed to lower branded pricing in line with expectations and weaker insecticide volumes amid challenged grower economics tied to geopolitical uncertainty, partially offset by strong Cyazypyr growth. It beat the consensus estimate of $72.4 million.

FMC’s FinancialsThe company had cash and cash equivalents of $390.9 million at the end of the quarter. Long-term debt was $2,770.6 million.

FMC’s FY2026 and Q2 OutlookFMC reaffirmed its full-year 2026 outlook, calling for revenue excluding India of $3.60 billion to $3.80 billion and adjusted EBITDA of $670 million to $730 million. Adjusted earnings per diluted share are still expected in the $1.63-$1.89 range, while free cash flow is projected between negative $65 million and positive $65 million.

The company’s full-year framework assumes interest expense of $255-$275 million and an adjusted tax rate of 16-18%, with depreciation and amortization of $160-$170 million. Capital additions and other investing activities are projected at $90-$110 million. FMC also expects the India contribution loss in 2026 to be roughly $90 million of revenue and $0 million of EBITDA.

For the second quarter, FMC expects revenue excluding India of $850 million to $900 million, with adjusted EBITDA of $130 million to $150 million and adjusted earnings per diluted share of 16-26 cents. The company expects year-over-year pressure to be driven largely by reduced orders from diamide partners and the removal of India from the reported base period.

FMC’s Price PerformanceShares of FMC have lost 61.9% in the past year compared with the industry’s 21.7% rise.

Image Source: Zacks Investment Research

FMC’s Zacks Rank & Key PicksFMC currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the basic materials space are CF Industries Holdings, Inc. (CF - Free Report) , Compass Minerals International, Inc. (CMP - Free Report) and Aris Mining Corporation (ARIS - Free Report) .

CF Industries is slated to report first-quarter 2026 results on May 6. The Zacks Consensus Estimate for earnings is pegged at $2.35 per share, indicating 27.03% year-over-year growth. CF sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. 

Compass Mineral is slated to report second-quarter fiscal 2026 results on May 6. The consensus estimate for CMP’s earnings per share is pegged at 66 cents. CMP presently carries a Zacks Rank #1.

Aris is scheduled to report first-quarter 2026 results on May 6. The Zacks Consensus Estimate for ARIS’s first-quarter earnings per share is pegged at 77 cents, indicating 381.25% year-over-year growth. ARIS carries a Zacks Rank #2 (Buy) at present.

FMC reported quarterly losses of 2 cents per share which beat the analyst consensus estimate of losses of 33 cents per share. The company reported quarterly sales of $758.600 million which beat the analyst consensus estimate of $744.406 million.

FMC affirmed its FY2026 adjusted EPS guidance of $1.63-$1.89 and sales guidance of $3.600 billion-$3.800 billion.

FMC shares fell 4.2% to trade at $14.71 on Friday.

These analysts made changes to their price targets on FMC following earnings announcement.

JP Morgan analyst Jeffrey Zekauskas maintained FMC with a Neutral and raised the price target from $15 to $16. RBC Capital analyst Arun Viswanathan maintained the stock with a Sector Perform and raised the price target from $16 to $17. Citigroup analyst Patrick Cunningham maintained FMC with a Neutral and boosted the price target from $15 to $17. Considering buying FMC stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ --

FMC Corporation (NYSE: FMC) today announced that Pierre Brondeau, FMC chairman, chief executive officer and president, and Andrew Sandifer, FMC executive vice president and chief financial officer, will speak at the BMO Global Farm to Market Chemicals Conference on May 14, 2026, at 1:15 p.m. Eastern Time.  A live webcast will be available at www.fmc.com/investors.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

SOURCE FMC Corporation

Also from this source

Meet FMC Corp (FMC +6.65%) -- an agricultural sciences company that serves farmers by offering crop protection technologies to increase productivity. It's been around for more than 140 years, and has some strong core values, such as "We do things the right way. We are ethical, keep our commitments, and take responsibility for our actions." And "We create innovative solutions while preserving the environment for tomorrow."

How has the company's stock performed for investors? Well, not so terrifically. Those who invested, say, $10,000 five years ago would now be holding a stake worth around $2,000. Yikes!

Image source: Getty Images.

That's an average annual loss of 27.6%, during a period when the S&P 500 averaged gains of 13.3%.

Looking forward That's a terrible result, but a more important question for current shareholders and would-be shareholders alike is where the stock is likely to go from here. Arguably, those shares seem undervalued at recent levels, with a forward-looking price-to-earnings (P/E) ratio of 9.1, well below the five-year average of 12.4.

Today's Change

(

6.65

%) $

0.75

Current Price

$

12.02

So what's the problem with FMC? Well, for one thing, it's carrying a lot of debt, in part due to acquisitions. It's also facing patent expirations for some key products. Worst of all, when the company reported its disappointing fourth-quarter results, management noted that it's exploring strategic options "including but not limited to the sale of the company."

Ugh, right? Well, on a more positive note, while revenue was down 12% year over year in the fourth quarter, the more recent first quarter of 2026 featured revenue down only 4%. The company is not necessarily doomed, though it has a lot of ground to regain. It's focusing on yield-boosting chemicals in a world where emerging markets will need to boost yields. It's selling its commercial India business to help pay down debt and is cutting costs.

It seems best to steer clear of FMC shares until its future is more clear and more rosy.

Selena Maranjian has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- 

FMC Corporation (NYSE: FMC) today announced that Andrew Sandifer, FMC executive vice president and chief financial officer, will speak at the 16th Annual Wells Fargo Industrials & Materials Conference on June 9, 2026, at 2:15 p.m. Central Time.  A live webcast will be available at www.fmc.com/investors.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

SOURCE FMC Corporation

Also from this source

A month has gone by since the last earnings report for FMC (FMC - Free Report) . Shares have lost about 11.8% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is FMC due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for FMC Corporation before we dive into how investors and analysts have reacted as of late.

FMC’s Q1 Earnings Beat Estimates on Volume Gains and FX TailwindFMC reported a first-quarter 2026 adjusted loss per share of 23 cents. This compares unfavorably to the year-ago quarter’s adjusted earnings per share of 18 cents. The result was narrower than the Zacks Consensus Estimate of a loss of 39 cents.

Quarterly revenues of $759 million declined 4% year over year but topped the consensus estimate of $721.8 million by 5.2%. Performance reflected favorable currency and stronger demand in select markets, partly offset by pricing pressure and partner-related volume headwinds. New active ingredient sales doubled year over year.

Profitability also declined as lower pricing and higher costs more than offset benefits from volume and currency. Tariffs and unfavorable raw material costs were the key cost headwinds, while lower R&D expenses provided some relief. The decline was also driven by tax charges related to higher valuation allowances, along with lower sales, higher restructuring costs and higher interest expense.

Regional Sales PerformanceNorth America sales increased 6% year over year to $198 million. FMC attributed the gain to high-teens sales growth for branded products led by herbicides, alongside solid growth in Plant Health and strong Cyazypyr performance. Sales topped the consensus estimate of $185.1 million.

EMEA revenues rose 13% to $307 million on solid branded volume growth led by herbicides and Cyazypyr. Branded pricing was similar to the year-ago quarter, while registration losses were in line with expectations and represented an estimated 5% headwind. It outpaced the consensus estimate of $282.4 million.

Latin America revenues fell 14% to $177 million. FMC cited lower branded volumes mainly for core portfolio products and a competitive market for core products that pressured branded pricing, though higher growth-portfolio sales led by Cyazypyr and new actives provided a partial offset. It missed the consensus estimate of $178.7 million.

Asia revenues, excluding India, declined 36% year over year to $81 million. The company pointed to lower branded pricing in line with expectations and weaker insecticide volumes amid challenged grower economics tied to geopolitical uncertainty, partially offset by strong Cyazypyr growth. It beat the consensus estimate of $72.4 million.

FinancialsThe company had cash and cash equivalents of $390.9 million at the end of the quarter. Long-term debt was $2.77 billion.

OutlookFMC reaffirmed its full-year 2026 outlook, calling for revenue excluding India of $3.6 billion to $3.8 billion and adjusted EBITDA of $670 million to $730 million. Adjusted earnings per diluted share are still expected in the $1.63-$1.89 range, while free cash flow is projected between negative $65 million and positive $65 million.

The company’s full-year framework assumes interest expense of $255-$275 million and an adjusted tax rate of 16-18%, with depreciation and amortization of $160-$170 million. Capital additions and other investing activities are projected at $90-$110 million. FMC also expects the India contribution loss in 2026 to be roughly $90 million of revenue and $0 million of EBITDA.

For the second quarter, FMC expects revenue excluding India of $850 million to $900 million, with adjusted EBITDA of $130 million to $150 million and adjusted earnings per diluted share of 16-26 cents. The company expects year-over-year pressure to be driven largely by reduced orders from diamide partners and the removal of India from the reported base period.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in fresh estimates.

The consensus estimate has shifted -47.5% due to these changes.

VGM ScoresAt this time, FMC has a poor Growth Score of F, a score with the same score on the momentum front. However, the stock has a grade of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, FMC has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ --

FMC Corporation (NYSE: FMC) today announced that Pierre Brondeau, FMC chairman, chief executive officer and president, and Andrew Sandifer, FMC executive vice president and chief financial officer, will speak at the Wolfe Research 3rd Annual Materials of the Future conference on June 17, 2026, at 9:15 a.m. Eastern Time.  A live webcast will be available at www.fmc.com/investors.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

SOURCE FMC Corporation

Also from this source